Moss on Adriamycin-based chemotherapy for breast cancer

[Guest guest]

DEPARTMENT OF CORRECTIONS

In a recent newsletter concerning the work of Dr. Dennis Slamon of UCLA,

I remarked that with the exception of the Annie Appleseed Project, no

one appeared to have noticed the article by Robert Bazell, NBC's chief

science correspondent, in which he commented on the statement by Dr.

Slamon that only 8 percent of women with breast cancer stand to benefit

from Adriamycin-based chemotherapy.

 

I was wrong. Annie Appleseed Project was not alone in picking up

Bazell's article on Dr. Slamon's work. In fact, the National Breast

Cancer Coalition also reviewed this important work, and has an extremely

helpful position paper on the subject at the NBCC Web site:

http://www.stopbreastcancer.org/bin/index.asp?strid=944 & depid=20

 

I apologize to NBCC for this omission.

--Ralph W. Moss, Ph.D.